SEC filing · 8-K

Insight Molecular Diagnostics Inc.: Material agreement

Insight Molecular Diagnostics entered into an amendment to modify royalty and sale payout terms related to CNI Monitor.

Filed September 21, 2026

Neutral news

What happened

On September 15, 2026, the company entered into Amendment No. 2 to the Chronix merger agreement with the equity holder representative.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to Insight Molecular Diagnostics Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.